Watch CEO Dr Michael Thurn’s February 2024 investor update.
OUR COMPANY
PharmAust is a clinical-stage biotechnology company developing new therapeutics for human and animal health applications. The company is repurposing monepantel for the treatment of cancer in dogs and neurodegenerative diseases in humans.
OUR SCIENCE
Monepantel is an approved veterinary product for the treatment of nematode infestations in sheep. In mammalian cells, monepantel is a potent inhibitor of the mTOR pathway. The mTOR pathway plays a central role in cell growth and proliferation of cancer cells.